First clinical multicenter experience with the new Pipeline Vantage flow diverter.

Area of Science:

• Neuroendovascular surgery
• Cerebrovascular disease management
• Medical device innovation

Background:

• Flow diversion is a key treatment for intracranial aneurysms.
• New flow diverters (FDs) aim to enhance treatment safety and efficacy.
• The Pipeline Vantage (PV) is a novel FD for aneurysm treatment.

Purpose of the Study:

• To evaluate the safety and feasibility of the Pipeline Vantage (PV) flow diverter.
• To assess the efficacy of the PV in treating intracranial aneurysms.
• To analyze procedural outcomes and complications associated with PV implantation.

Main Methods:

• Retrospective analysis of patients treated with PV across 10 international centers.
• Inclusion of patient and aneurysm characteristics, procedural details, and complication data.
• Assessment of aneurysm occlusion rates post-treatment.

Main Results:

• Successful PV implantation in all 61 treatment sessions for 70 aneurysms in 60 patients.
• Technical complications occurred in 24.6% but were asymptomatic; symptomatic complication rate was 8.2%.
• Complete aneurysm occlusion achieved in 77.9% at a mean 7.1-month follow-up.

Conclusions:

• The Pipeline Vantage flow diverter demonstrates safety and feasibility for intracranial aneurysms.
• Promising short-term occlusion rates warrant further investigation in long-term studies.
• The PV represents a viable option in the neuroendovascular treatment of aneurysms.